AstraZeneca: completes divestment of Crestor rights
(CercleFinance.com) - AstraZeneca announces that it has completed the transfer of the rights to Crestor (rosuvastatin) and related drugs, in over 30 European countries, to Grünenthal.
The rights in the UK and Spain were not included in the agreement.
Under the terms of the agreement, AstraZeneca received a payment of 320 million dollars from Grünenthal and may also be eligible for future milestone payments of up to 30 million dollars.
The upfront payment will be booked in AstraZeneca's financial statements in other operating income and expenses in the first quarter of 2021.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The rights in the UK and Spain were not included in the agreement.
Under the terms of the agreement, AstraZeneca received a payment of 320 million dollars from Grünenthal and may also be eligible for future milestone payments of up to 30 million dollars.
The upfront payment will be booked in AstraZeneca's financial statements in other operating income and expenses in the first quarter of 2021.
Copyright (c) 2021 CercleFinance.com. All rights reserved.